Jacob Gottlieb and Stuart Weisbrod are two of the most prominent figures in the world of healthcare investing today. Before spending the last twenty years running two highly successful funds, the worked together at Merlin BioMed Group. Now the pair of investment gurus has found themselves sharing offices together and planning a major collaboration project.
Stuart Weisbrod is the co-founder of Merlin which was begun in 1998. The firm is an investment management firm that focuses on companies in the healthcare sector with portfolios related to the pharmaceutical industry, biotechnology and the healthcare service sector. Weisbrod had a long and successful track record of success investing in the healthcare sector prior to founding Merlin. Prior to founding the firm, he held positions with Merrill Lynch and Oracle Partners among others. He also holds a PhD from Princeton Universty which he received back in 1980.
Merlin enjoyed many years of success in the investment industry but finally closed up shop in 2007. After the end of Merlin, Weisbrod founded Iguana Healthcare Partners, a company that operates with an investment strategy that is very similar to the one that was employed by Merlin. Gottlieb has also seen great success since he left Merlin. He founded Visium Asset Management which he has subsequently built into an $8 billion valued hedge fund. Though Visium was highly successful the firm closed down operations in 2016. It was after this that the two previous colleagues Gottlieb and Weisbrod have come back together for what promises to be a truly exciting future collaboration.
Jacob Gottlieb has entered into a venture called Altium Capital since Visum ended. The first major investment that Altium has made is with promising pharmaceutical operation Oramed Pharmaceuticals Inc. Oramed has a massive potential to change the lives of millions of people around the world who are suffering from diabetes. It is this promise that has attracted a mind the likes of Jacob Gottlieb.